Study Shows Potential Benefits of Newer, Non-Egg-Based Flu Vaccines – Global Biodefense

A new study reports that multiple seasons of being vaccinated with non-egg-based flu vaccines may help refocus peoples vaccine-induced immune responses to better target circulating influenza viruses.

For more than 70 years, most influenza (flu) vaccines have been produced by growing influenza viruses in chicken eggs. One drawback of this production method is that it often introduces changes to the viruses as they adapt to grow in eggs. These so-called egg-adapted changes can render the vaccine viruses significantly different from circulating wild flu viruses. As a result, egg-based vaccines can prompt a persons immune system to direct antibodies at targets, or epitopes, on the vaccine viruses that are not found on circulating viruses. This could result in reduced vaccine effectiveness (VE). Research has shown this antibody response could be reinforced by repeated egg-based vaccination, which could contribute to further reductions in VE over time.

Two non-egg-based flu vaccinesthe recombinant flu vaccine and the cell culture-based flu vaccinewere introduced in the United States during the 2013-14 flu season. The study, which looked at data from a randomized clinical trial conducted during the 2018-2019 and 2019-2021 influenza seasons, compared antibody responses following vaccination with recombinant, cell culture-based, or standard egg-based influenza vaccines among 1,400 people.

The results indicate that vaccination with recombinant influenza vaccine induced the most robust antibody responses against multiple vaccine viruses. They also indicate that repeated vaccination with non-egg-based flu vaccines could overcome the effect of prior repeated vaccination with egg-based vaccines. Redirecting the antibody responses away from egg-adapted epitopes resulted in higher antibody responses to cell-grown viruses that better represent circulating viruses.

The findings could inform decision-making related to optimal vaccination strategies for people in different age groups and populations.

For one, vaccination with non-egg-based flu vaccines could be especially beneficial for people who have been repeatedly vaccinated with egg-based vaccines. This could include health care personnel who have annual vaccination requirements and older adults, who tend to have been vaccinated more frequently than other groups of people. The study also adds to the evidence that when young children are first immunized against influenza, they may benefit from getting a non-egg-based vaccine, as a persons first exposure to influenza virus can play a role in shaping their immune response to subsequent influenza virus infection or flu vaccinations.

Currently, recombinant and cell-based flu vaccines are the only flu vaccines made without the use of eggs that are licensed for use in the United States. The flu viruses used in the cell-based vaccines are grown in cultured cells of mammalian origin. Recombinant flu vaccines do not require the use of a candidate vaccine virus (CVV) for production because they are created synthetically.

Some observational studies have shown greater protection against flu among people who received cell-based inactivated influenza vaccines compared with those who received standard-dose egg-based vaccines. Nevertheless, egg-based vaccines remain the most widely available flu vaccines and are an important preventive tool. The benefits of vaccination with any flu vaccine, including egg-based flu vaccine, still far outweigh the potential risks of not getting vaccinated. Currently CDC does not have a preference for the use of any one flu vaccine over another except among people 65 years and older. When available, CDC recommends people 65 years and older get a high-dose, an adjuvanted, or a recombinant flu vaccinebecause a review of existing studies suggested that, in this age group, these vaccines are potentially more effective than standard-dose unadjuvanted flu vaccines.

Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines. Nature Communications, 4 January 2024.

READ ALSO:

Recombinant or Standard-Dose Influenza Vaccine in Adults under 65 Years of Age

In this cluster-randomized observational study, Kaiser Permanente Northern California facilities routinely administered either a high-dose recombinant influenza vaccine (Flublok Quadrivalent) or one of two standard-dose influenza vaccines during the 20182019 and 20192020 influenza seasons to adults 50 to 64 years of age (primary age group) and 18 to 49 years of age. he high-dose recombinant vaccine conferred more protection against PCR-confirmed influenza than an egg-based standard-dose vaccine among adults between the ages of 50 and 64 years. NEJM

Leveraging Modernization of the US Influenza Vaccine Manufacturing Base to Make Better Vaccines: A Work in Progress

Initial efforts to build up domestic vaccine manufacturing started in 2004. HHS funded contracts to bolster supplies of embryonated eggs so they were available year-round and to develop a cell-based influenza vaccine with a provision to build a domestic facility for vaccine production. BARDA followed these contracts with additional cell-based influenza vaccine, adjuvant, recombinant influenza vaccine, and influenza vaccine production facility contracts. In parallel, the DoD funded the development of alternate platforms for influenza vaccine production. These efforts have resulted in the licensure of new cell-based, recombinant, and adjuvanted or dose-sparing influenza vaccines. While the use of non-egg-based vaccines is growing, the field effectiveness data in the years since their licensure suggest that we are still being served by mediocre vaccines. Vaccine Insights

Development of Cross-Reactive Live Attenuated Influenza Vaccine Candidates against Both Lineages of Influenza B Virus

The urgent need for broadly protective influenza B virus vaccines is underscored by the significant burden in the human population and the relatively high mutation rate of these viruses. A reverse genetics (RG) system is required to rapidly update the antigenic composition of vaccines, as well as to design LAIVs with a broader spectrum of protection. Such a system has been developed for the Russian LAIVs only for type A strains, but not for influenza B viruses (IBV). Vaccines

Go here to read the rest:

Study Shows Potential Benefits of Newer, Non-Egg-Based Flu Vaccines - Global Biodefense